Syrup 30 mg/5 ml
Cough is one of the most common complaints with which people consult a doctor.1 It can be a symptom of a number of diseases and conditions that require medications that affect the viscosity of sputum and have an expectorant effect. And one of the frequently used mucolytic agents in Russia is Lazolvan®, used in adults and children.2 It is available in various forms, including syrup with a dosage of 30 mg/5 ml, intended for use in adult practice.
Use during pregnancy
The active ingredient of Lazolvan® syrup, ambroxol, penetrates the hematoplacental barrier, which separates the blood circulation of the mother and fetus. Consequently, when a woman takes the drug, it enters the child’s blood. The experience of using the drug in pregnant women after 28 weeks is quite extensive. Both clinical practice data and the results of animal studies have not demonstrated any undesirable effects of Lazolvan® on the health of the growing fetus, the course of pregnancy, childbirth, or the condition of the child after birth. In addition, the use of ambroxol in the second and third trimesters of pregnancy (after 28 weeks) has been deeply studied. The research results confirmed that ambraxol does not have a negative effect on the fetus.3
However, when prescribing medication to expectant mothers, a healthcare professional takes into account several factors and carefully weighs the balance between the benefit to the woman and the risk to the developing fetus.3, 4 Special precautions when using medications are observed during critical periods of pregnancy, in particular before 12 weeks, when all the organs and systems of the unborn child are formed. Therefore, it is not recommended to take Lazolvan® syrup in the first trimester.3, 5 But in the second and third trimesters, a cough drug based on ambroxol can be prescribed after a thorough assessment of the potential benefit to the mother and the possible risk to the fetus.4
When breastfeeding
Many medications are excreted in breast milk and, accordingly, enter the baby’s body with it. The concentration of the active substance in the baby’s blood depends on various factors, including the duration of feeding, the volume of milk the child received, and the child’s body’s ability to eliminate the drug. Because a breastfed baby's digestive system is immature, the half-life of drugs in the baby's body may be much longer than in the mother's body.5
Medicines that pass into breast milk include Lazolvan® syrup. Despite the fact that in therapeutic doses it did not have a negative effect on the child, it is not recommended to be taken during breastfeeding. Moreover, lactation, according to the instructions for use, is a contraindication to the use of Lazolvan® syrup.3
If kidney function is impaired
In kidney disease, the elimination of drugs is impaired. As a rule, this takes much longer than usual. In this regard, medications for impaired renal function are prescribed very carefully. Before recommending a drug, a healthcare professional will consider possible changes in the rate of elimination, taking into account a number of factors, including what drug is being prescribed, the severity of the kidney problem in a particular case, and so on. Only after a thorough assessment does a healthcare professional decide to prescribe the medication and adjust the dosage individually.6
For liver disorders
One of the main functions of the liver is the breakdown of substances entering the body, including medications. When a person is healthy, this process occurs harmoniously and efficiently. However, in some cases, when liver function is impaired, medications that are not normally harmful to humans can become toxic. Particular care must be taken in severe liver disease such as cirrhosis.7
The active ingredient of Lazolvan® syrup, ambroxol, like other drugs, is metabolized in the liver. Therefore, if its operation is disrupted, it is necessary to take the medicine with caution, as indicated in the instructions for use, and as prescribed by a healthcare professional.3
Active substance
The active substance of the drug Lazolvan® syrup is ambroxol hydrochloride. It helps to enhance the transport of sputum, improve its discharge and relieve cough.
The dosage of the active substance (ambroxol) is 30 mg in 5 ml of syrup, which is a clear viscous liquid with a pleasant strawberry aroma.3
Lazolvan cough remedy with sputum syrup for adults 30 mg/5ml 100ml
A country
France
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Ambroxol
Compound
Active substance: Ambroxol hydrochloride.
pharmachologic effect
Studies have shown that ambroxol, the active ingredient in the drug, increases secretion in the respiratory tract. It enhances the production of pulmonary surfactant and stimulates ciliary activity. These effects lead to increased mucus flow and transport (mucociliary clearance). Increasing mucociliary clearance improves sputum discharge and relieves cough. In patients with chronic obstructive pulmonary disease, long-term drug therapy (for at least 2 months) led to a significant reduction in the number of exacerbations. There was a significant decrease in the duration of exacerbations and the number of days of antibiotic therapy. Pharmacokinetics. All dosage forms of immediate release ambroxol are characterized by rapid and almost complete absorption with a linear dependence on the dose in the therapeutic concentration range. The maximum concentration in plasma after oral administration is achieved after 1 - 2.5 hours. The distribution volume is 552 l. In the therapeutic concentration range, binding to plasma proteins is approximately 90%. The transition of ambroxol from the blood to tissues when administered orally occurs quickly. The highest concentrations of the active component of the drug are observed in the lungs. Approximately 30% of an oral dose is subject to first pass effects through the liver. Studies on human liver microsomes have shown that CYP3A4 is the predominant isoform responsible for the metabolism of ambroxol to dibromoantranilic acid. The remainder of ambroxol is metabolized in the liver, mainly by glucuronidation and by partial degradation to dibromoantranilic acid (approximately 10% of the administered dose), as well as a small number of additional metabolites. The terminal half-life of ambroxol is 10 hours. Total clearance is within 660 ml/min, renal clearance accounts for approximately 83% of the total clearance. No clinically significant effect of age and gender on the pharmacokinetics of ambroxol was found. therefore, there is no basis for selecting the dosage based on these characteristics.
Indications for use
Acute and chronic diseases of the respiratory tract with the release of viscous sputum: acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty in sputum discharge, bronchiectasis.
Mode of application
Orally. Adults and children over 12 years old: 5 ml 3 times a day; children from 6 to 12 years old: 2.5 ml 2-3 times a day. The drug can be used regardless of meals. If symptoms of the disease persist in Within 4-5 days from the start of treatment, it is recommended to consult a doctor.
Interaction
No clinically significant, undesirable interactions with other drugs have been reported. Increases the penetration of amoxicillin and cefuroxime into the bronchial secretions. erythromycin.
Side effect
Disorders of the gastrointestinal tract. Often - nausea, decreased sensitivity in the mouth or pharynx; uncommon - dyspepsia, vomiting, diarrhea, abdominal pain, dry mouth; rarely - dry throat. Immune system disorders, damage to the skin and subcutaneous tissues. Rarely - rash, urticaria; anaphylactic reactions (including anaphylactic shock), angioedema, itching, hypersensitivity. Disorders of the nervous system. Often - dysgeusia (impaired taste).
Contraindications
Hypersensitivity to ambroxol or other components of the drug, pregnancy (first trimester), lactation period, children under 6 years of age.
Overdose
Specific symptoms of overdose in humans have not been described. There have been reports of accidental overdose and/or medical error, resulting in symptoms of known side effects of the drug: nausea, dyspepsia, vomiting, diarrhea, abdominal pain. In this case, there may be a need for symptomatic therapy. Treatment: artificial vomiting, gastric lavage in the first 1-2 hours after taking the drug; symptomatic therapy.
special instructions
The syrup contains 5 g of sorbitol based on the maximum recommended daily dose (20 ml). Patients with rare hereditary fructose intolerance should not take this drug. Use the drug with caution during pregnancy (II - III trimester), with renal and/or liver failure. Use during pregnancy and breastfeeding. Ambroxol penetrates the placental barrier. Preclinical studies have not revealed direct or indirect adverse effects on pregnancy, embryonic/fetal, postnatal development and labor. General clinical experience with the use of ambroxol after 28 weeks of pregnancy has not found evidence of a negative effect of the drug on the fetus. However, the usual precautions must be observed when using the medicine during pregnancy. It is especially not recommended to take the drug in the first trimester of pregnancy. In the second and third trimesters of pregnancy, use of the drug is possible only if the potential benefit to the mother outweighs the potential risk to the fetus. Ambroxol can be excreted in breast milk. Despite the fact that no undesirable effects were observed in breast-fed children, it is not recommended to use the drug during lactation. It should not be combined with antitussives that impede the removal of mucus. The sorbitol contained in the syrup may have a mild laxative effect. In patients with severe skin lesions - Stevens-Johnson syndrome or toxic epidermal necrolysis - in the early phase, fever, body pain, rhinitis, cough and sore throat may appear. During symptomatic treatment, it is possible to erroneously prescribe mucolytic agents such as ambroxol hydrochloride. There are isolated reports of the detection of Stevens-Johnson syndrome and toxic epidermal necrolysis. coinciding with the prescription of the drug; however, there is no cause-and-effect relationship with taking the drug. If the above syndromes develop, it is recommended to stop treatment and immediately seek medical help. If kidney function is impaired, the drug should be used only on the recommendation of a doctor. The effect of the drug on the ability to drive vehicles and machines. There have been no cases of the drug affecting the ability drive vehicles and machinery. Studies on the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions have not been conducted.
